UCB propels Vimpat monotherapy along Keppra path, but can it beat Keppra?
This article was originally published in Scrip
Executive Summary
UCB has reported positive Phase III data that shows that its anti-epileptic drug, lacosamide (Vimpat) performs better when used as monotherapy than when used an adjunct. This data, the company said, will be included as part of a supplemental new drug application (sNDA) submission to the US FDA in the second half of this year.